Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (19)
Blood Cancer Journal (8)
Journal of Exposure Science and Environmental Epidemiology (2)
Bone Marrow Transplantation (2)
European Journal of Clinical Nutrition (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (37)
Reviews (5)
Correspondence (3)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Biophysics
Biotechnology
Cancer
Cell biology
Computational biology and bioinformatics
Diseases
Drug discovery
Genetics
Health care
Immunology
Materials science
Mathematics and computing
Medical research
Oncology
Physics
Psychology
Risk factors

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–46 of 46 results

Advanced filters: Author: K. Weisel Clear advanced filters

The amino acid sequence of the α-chain of human fibrinogen

R. F. Doolittle
K. W. K. Watt
M. Riley
Research01 Aug 1979
Nature

Volume: 280, P: 464-468
Temporal genomic dynamics shape clinical trajectory in multiple myeloma

This analysis of whole-genome sequencing data from 421 multiple myeloma samples elucidates the timing of key genomic events and shows associations between the timing of 1q gain and clinical outcome.

Francesco Maura
Marcella Kaddoura
Niels Weinhold
Research20 Aug 2025
Nature Genetics

Volume: 57, P: 2203-2214
Internet-based indicated prevention of anxiety and depression disorder onset three-arm randomized clinical trial

Anna-Carlotta Zarski
Kiona K. Weisel
David D. Ebert
ResearchOpen Access01 Oct 2025
npj Digital Medicine

Volume: 8, P: 1-7
Radiocarbon test of earthquake magnitude at the Cascadia subduction zone

Brian F. Atwater
Minze Stuiver
David K. Yamaguchi
Research12 Sept 1991
Nature

Volume: 353, P: 156-158
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma

Aneta Schieferdecker
Sebastian Hörber
Katja Weisel
ResearchOpen Access09 Jan 2020
Blood Cancer Journal

Volume: 10, P: 1-9
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement

Maximilian J. Steinhardt
Christoph Schaefers
Leo Rasche
ResearchOpen Access30 Jul 2025
Blood Cancer Journal

Volume: 15, P: 1-7
High efficiency transduction of human VEGF₁₆₅ into human skeletal myoblasts: in vitro studies

Lei Ye
Husnain Kh Haider
Eugene KW Sim
ResearchOpen Access01 Oct 2003
Experimental & Molecular Medicine

Volume: 35, P: 412-420
The Histological Classification of Lower Respiratory Tract Tumours

N K Shinton
Research01 Jun 1963
British Journal of Cancer

Volume: 17, P: 213-221
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

H Ludwig
M Delforge
P Sonneveld
ReviewsOpen Access18 Dec 2017
Leukemia

P: 1-46
Exploring effects of platelet contractility on the kinetics, thermodynamics, and mechanisms of fibrin clot contraction

Evgenii Kliuchnikov
Alina D. Peshkova
Valeri Barsegov
ResearchOpen Access24 Feb 2025
npj Biological Physics and Mechanics

Volume: 2, P: 1-18
Fibrin Clots Are Equilibrium Polymers That Can Be Remodeled Without Proteolytic Digestion

Irina N. Chernysh
Chandrasekaran Nagaswami
John W. Weisel
ResearchOpen Access20 Nov 2012
Scientific Reports

Volume: 2, P: 1-6
CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype

Prior antigenic exposure induces cognate memory responses in B cells. Shlomchik and colleagues show that CD80 and PD-L2 define functionally distinct memory B cells.

Griselda V Zuccarino-Catania
Saheli Sadanand
Mark J Shlomchik
Research01 Jun 2014
Nature Immunology

Volume: 15, P: 631-637
Increased long-term health risks attributable to select volatile organic compounds in residential indoor air in southeast Louisiana

Jeffrey K. Wickliffe
Thomas H. Stock
Emily Harville
ResearchOpen Access10 Dec 2020
Scientific Reports

Volume: 10, P: 1-12
Sarcomatoid renal cell carcinoma: biology, natural history and management

In this Review, Blum et al. summarize the current knowledge on sarcomatoid renal cell carcinoma, a diagnosis characterized by the presence of sarcomatoid dedifferentiation and a poor prognosis. They discuss the origin, presentation, molecular biology and treatment of this disease.

Kyle A. Blum
Sounak Gupta
A. Ari Hakimi
Reviews13 Oct 2020
Nature Reviews Urology

Volume: 17, P: 659-678
Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

K. Forde
K. Cocks
C. Kyriakou
ReviewsOpen Access16 May 2023
Blood Cancer Journal

Volume: 13, P: 1-15
House dust levels of selected insecticides and a herbicide measured by the EL and LWW samplers and comparisons to hand rinses and urine metabolites

P J LIOY
R D EDWARDS
K SEXTON
Research01 Aug 2000
Journal of Exposure Science & Environmental Epidemiology

Volume: 10, P: 327-340
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Katja C. Weisel
Christof Scheid
Hartmut Goldschmidt
ResearchOpen Access08 Apr 2019
Blood Cancer Journal

Volume: 9, P: 1-4
Reducing postpartum weight retention through a correspondence intervention

EA Leermakers
K Anglin
RR Wing
Research29 Oct 1998
International Journal of Obesity

Volume: 22, P: 1103-1109
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Thierry Facon
Philippe Moreau
Shaji K. Kumar
ResearchOpen Access27 Feb 2025
Leukemia

Volume: 39, P: 942-950
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study

Philippe Moreau
Thierry Facon
Shaji K. Kumar
Research15 Jan 2025
Leukemia

Volume: 39, P: 710-719
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Elias K. Mai
Kaya Miah
Hartmut Goldschmidt
Amendments and CorrectionsOpen Access16 Nov 2021
Leukemia

Volume: 35, P: 3636
CD8⁺ CD28⁻ regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Katharina Kriegsmann
Gigi Nu Hoang Quy Ton
Michael Hundemer
ResearchOpen Access03 Jun 2024
Leukemia

Volume: 38, P: 1621-1625
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

Katja Weisel
Maria-Victoria Mateos
Philippe Moreau
ResearchOpen Access16 Oct 2020
Leukemia

Volume: 35, P: 1732-1744
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Lisa B. Leypoldt
Britta Besemer
Katja C. Weisel
ResearchOpen Access03 Nov 2021
Leukemia

Volume: 36, P: 885-888
Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire

K Klipstein-Grobusch
JH den Breeijen
JCM Witteman
Research10 Aug 1998
European Journal of Clinical Nutrition

Volume: 52, P: 588-596
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Elias K. Mai
Stefanie Huhn
Niels Weinhold
ResearchOpen Access04 Jan 2023
Blood Cancer Journal

Volume: 13, P: 1-9
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

P. Ahmadi
W. Alsdorf
K. Weisel
CorrespondenceOpen Access22 Jan 2025
Bone Marrow Transplantation

Volume: 60, P: 538-540
Is macronutrient composition of dietary intake data affected by underreporting? Results from the EPIC-Potsdam study

S Voss
A Kroke
H Boeing
Research23 Mar 1998
European Journal of Clinical Nutrition

Volume: 52, P: 119-126
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Elias K. Mai
Thomas Hielscher
Hartmut Goldschmidt
ResearchOpen Access07 Dec 2023
Leukemia

Volume: 38, P: 640-647
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Meletios A. Dimopoulos
Sagar Lonial
Paul G. Richardson
ResearchOpen Access04 Sept 2020
Blood Cancer Journal

Volume: 10, P: 1-10
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Hans Salwender
Ahmet Elmaagacli
Hartmut Goldschmidt
Research24 May 2021
Leukemia

Volume: 35, P: 3007-3011
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Elias K. Mai
Thomas Hielscher
Hartmut Goldschmidt
Research29 Jun 2018
Leukemia

Volume: 33, P: 258-261
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Marc-Andrea Baertsch
Elias K. Mai
Hartmut Goldschmidt
ResearchOpen Access07 Jan 2021
Blood Cancer Journal

Volume: 11, P: 1-10
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Hartmut Goldschmidt
Elias K. Mai
Hans J. Salwender
Research07 Feb 2020
Leukemia

Volume: 34, P: 1853-1865
Standalone smartphone apps for mental health—a systematic review and meta-analysis

Kiona K. Weisel
Lukas M. Fuhrmann
David D. Ebert
ReviewsOpen Access02 Dec 2019
npj Digital Medicine

Volume: 2, P: 1-10
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Elias K. Mai
Kaya Miah
Hartmut Goldschmidt
ResearchOpen Access20 Jul 2020
Leukemia

Volume: 35, P: 809-822
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Maria Gavriatopoulou
Ajai Chari
Meletios Athanasios Dimopoulos
ResearchOpen Access24 Feb 2020
Leukemia

Volume: 34, P: 2430-2440
Exploring the utility of robots in exposure studies

Elisabeth Feld-Cook
Rahul Shome
Jennifer (Mi K.) Shin
ResearchOpen Access19 Nov 2019
Journal of Exposure Science & Environmental Epidemiology

Volume: 31, P: 784-794
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

H Goldschmidt
H M Lokhorst
P Sonneveld
Research04 Jul 2017
Leukemia

Volume: 32, P: 383-390
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E K Mai
U Bertsch
H Goldschmidt
Research19 Mar 2015
Leukemia

Volume: 29, P: 1721-1729
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

S Huhn
N Weinhold
H Goldschmidt
CorrespondenceOpen Access15 May 2017
Bone Marrow Transplantation

Volume: 52, P: 1194-1198
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

H Ludwig
K Weisel
M Engelhardt
CorrespondenceOpen Access11 Jan 2017
Leukemia

Volume: 31, P: 997-1000
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

W-J Chng
H Goldschmidt
R Hájek
ResearchOpen Access27 Dec 2016
Leukemia

Volume: 31, P: 1368-1374
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

P Moreau
D Joshua
M A Dimopoulos
ResearchOpen Access04 Jul 2016
Leukemia

Volume: 31, P: 115-122
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini

D J Kowalewski
S Walz
J S Stickel
ResearchOpen Access08 Apr 2016
Blood Cancer Journal

Volume: 6, P: e411
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

M A Dimopoulos
X Leleu
J F S Miguel
ReviewsOpen Access05 Feb 2014
Leukemia

Volume: 28, P: 1573-1585